APA (7th ed.) Citation

Center for Biologics Evaluation and Research (U.S.). (2008). Guidance for industry: Safety, efficacy, and pharmacokinetic studies to support marketing of immune globuline intravenous (human) as replacement therapy for primary humoral immunodeficiency. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research.

Chicago Style (17th ed.) Citation

Center for Biologics Evaluation and Research (U.S.). Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globuline Intravenous (human) as Replacement Therapy for Primary Humoral Immunodeficiency. Rockville, MD: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2008.

MLA (9th ed.) Citation

Center for Biologics Evaluation and Research (U.S.). Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globuline Intravenous (human) as Replacement Therapy for Primary Humoral Immunodeficiency. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2008.